騰盛博藥尾盤拉昇漲超11% 最新披露稱新冠特效藥對奧密克戎仍保持良好活性
格隆匯12月22日丨騰盛博藥-B(2137.HK)尾盤拉昇一度漲11.31%至37.9港元,最終收漲10.57%報37.65港元,市值271億港元。騰盛博藥在昨日召開的線上媒體會上進一步披露,其子公司騰盛華創研發的新冠中和抗體藥物安巴韋單抗/羅米司韋單抗聯合療法中,安巴韋單抗對於奧密克戎突變株的活性降低,但仍有一定的抑制效果,在高濃度的情況下,可以抑制90%以上的病毒。而羅米司韋單抗對奧密克戎突變株的活性完全沒有變化。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.